Alpine Immune Is Weighing Options After Takeover Interest [BNN Bloomberg (Canada)]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: BNN Bloomberg
weighing options including a potential sale after attracting takeover interest, according to people with knowledge of the matter. The stock gained as much as 17%. The Seattle-based company is working with advisers to weigh a potential transaction, said the people, who asked not to be identified discussing confidential information. At least one larger pharmaceutical company has spoken to the company about a potential takeover, the people said. Deliberations are ongoing and there's no certainty that Alpine Immune will decide to pursue a sale, the people said. A representative for Alpine Immune declined to comment. Alpine rose 7.9% to $42 at 12:42 p.m. in New York trading Wednesday, giving the company a market value of about $2.8 billion. The stock is up 451%% in the past year. Founded in 2015, Alpine Immune develops treatments for autoimmune and inflammatory diseases. It's set to present updated data on April 15 about the safety and effectiveness of its lead product, Povetacicep
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding [Yahoo! Finance]Yahoo! Finance
- Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- CAR T-Cell Therapy Market to Reach Valuation of USD 22.2 Billion By 2032: Astute Analytica [Yahoo! Finance]Yahoo! Finance
- Cell and gene therapy companies trip at scalability hurdle [Yahoo! Finance]Yahoo! Finance
- Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- NVS's page on the SEC website